Mahmoud Soliman Iews

Mahmoud Soliman Iews

Auto-generated profile, based on publicly available information

Mahmoud Soliman Iews

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynaecology, Faculty of Medicine, University of British Columbia, Vancouver, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2023 in Human Reproduction
Verified
Journal Article
Closed access
PDF file
MBMohamed Ali Bedaiwy
Mohamed Ali Bedaiwy
BFBahi Fayek
Bahi Fayek
EYEmily C Yang
Emily C Yang
MIMahmoud S Iews
Mahmoud S Iews
Mohamed ElgendiMohamed Elgendi
Mohamed Elgendi
FHFaten F Abdel Hafez
Faten F Abdel Hafez
Does the occurrence of non-visualized pregnancy loss (NVPL) affect future reproductive outcomes in patients with recurrent pregnancy loss (RPL)? The number of previous NVPLs is a significant predictor of subsequent live birth in patients with RPL. The number of preceding miscarriages is a strong indicator for future reproductive outcomes. However, NVPL particularly has been sparsely addressed in previous literature. We performed a retrospective cohort study of 1981 patients attending a specialized recurrent pregnancy loss clinic (RPL) from January 2012 to March 2021. A total of 1859 patients met the inclusion criteria of the study and were included in the analysis. Patients with a history of RPL, defined as ≥2 pregnancy losses before 20 weeks gestation, who attended a specialized RPL clinic in a tertiary care center were included. Patients’ evaluation included parental karyotyping, antiphospholipid antibodies screening, uterine cavity assessment with hysterosalpingography (HSG) or hysteroscopy, maternal thyroid stimulating hormone (TSH) testing, and serum hemoglobin A1C testing. Other investigations were performed only when indicated such as testing for inherited thrombophilias, serum prolactin, oral glucose tolerance test, and endometrial biopsy. Patients were divided into three groups; patients who experienced NVPLs only (pure NVPLs group), patients with only visualized pregnancy losses (pure VPLs group), and patients with history of both NVPLs and VPLs (mixed group). Statistical analysis was performed using Wilcoxon rank-sum tests for continuous variables and Fisher’s exact tests for categorical variables. Significance was detected when P values <0.05. A logistic regression model was used to determine the impact of NVPLs and VPLs numbers on any live birth subsequent to the initial RPL clinic visit. The prevalence of patients with pure NVPLs, pure VPLs, and mixed losses was 14.7% (274/1859), 31.8% (591/1859), and 53.5% (994/1859), respectively. The prevalence of acquired and congenital uterine anomalies diagnosed by HSG or hysteroscopy was significantly different between pure NVPLs, pure VPLs, and mixed groups (16.8% versus 23.7% versus. 20.7%, respectively P = 0.05). There were no significant differences in the results of other RPL investigations or baseline demographics between the three groups. A logistic regression model controlling for maternal age at the initial RPL clinic visit and the follow-up duration showed that the numbers of NVPLs (odds ratio (OR): 0.77, CI: 0.68–0.88) and VPLs (OR: 0.75, CI: 0.64–0.86) are strong predictors for subsequent live births after the initial RPL clinic visit (P < 0.001). The odds of having a live birth decreased by 23% and 25% with each additional NVPL and VPL, respectively. This study may be limited by its retrospective design. Some of our data, including home pregnancy tests and obstetric history, are based on patient self-reporting, which could have overstated the true prevalence of NVPLs. Another limitation is the lack of available live birth data for all patients at the time of the analysis. To our knowledge, this is the first study to examine and analyze the reproductive outcomes of patients with pure NVPLs in a substantial cohort of patients with RPL. NVPLs seem to affect future live births the same way as clinical miscarriages, which supports their inclusion in RPL definitions. This study was supported in part by Canadian Institute Heath Grant (CIHR): Reference Number/W11-179912 and Women's Health Research Institute (WHRI), Vancouver, BC, Canada. M.A.B: Research grants from Canadian Institute for Health Research (CIHR) and Ferring Pharmaceutical. M.A.B. is on the advisory board for AbbVie and Baxter. N/A.

1 May 2023 in Reproductive Sciences
Verified
Journal Article
Closed access
PDF file
AAAmr Abdelkareem
Amr Abdelkareem
MIMahmoud S. Iews
Mahmoud S. Iews
AAAbdou S. Ait-Allah
Abdou S. Ait-Allah
SRSalah M. Rasheed
Salah M. Rasheed
YHYasser A. Helmy
Yasser A. Helmy
MBMohamed Ali Bedaiwy
Mohamed Ali Bedaiwy

10 March 2021 in SVU-International Journal of Medical Sciences
Verified
Journal Article
Open access
MIMahmoud Soliman Iews
Mahmoud Soliman Iews
MAMohammad Abu Al-Fadl Ashashy
Mohammad Abu Al-Fadl Ashashy
MAMahmoud Ibrahim Almolakab B Alrashedy
Mahmoud Ibrahim Almolakab B Alrashedy
MHMahmoud Khairy El Haish
Mahmoud Khairy El Haish
MMMohammad Abd El Rahman Mohammad
Mohammad Abd El Rahman Mohammad
Background: The combinations between heart disorders and gestation could be challenging to the physician managing the mother and fetus together. Gestation afterward mechanical heart valve replacements require critical coagulation controlling. Specific consideration must be given to the incidence of complications throughout anti-coagulation treatment. Objectives: was to evaluate the outcome of the antenatal, natal and postnatal outcome of women with prosthetic valve with pregnancy according to the local policies and protocols in our department. Patients and methods: This study was a cohort one that was demonstrated at Obstetrics and Gynecology dep., Qena Faculty of medicine, South Valley University in the period between July 2019 to 30th of June 2020. Results: The results of current study showed a positive correlation between dose of warfarin and neonatal outcome as in group A ( 64% with good outcome , 11.8% misscarige) compared with group B (22.2% with good outcome 38.9% misscarige), and good fetal / neonatal outcome was observed in(42.9% )of cases. The miscariage rate was (25.7%). Congenital anomaly was seen in (8.6%). Furthermore, (22.9%) of pregnancies ended as IUFD. Conclusion: Warfarin as an anticoagulant for pregnant women with prosthetic valve throghout pregnancy seems to be secure for the mothers due to a lesser occurrence of thromboembolic conditions than un-fractionated or lower-molecular-weight heparin. The fetal / neonatal outcome is good especially if doses not exceed 5mg.